RPS6KA3 and melanoma: Our results reveal that RSK2 not only promotes melanoma cell proliferation, but also mediates vemurafenib resistance through the upregulation of cyclin D1 mediated by accelerating the degradation of FOXO1 by phosphorylation (Figure 6H).